SCHEMBL1107005

SCHEMBL1107005

CC(C)OCc1ccoc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50
CETP P11597 1/20 0.41
ACACB O00763 2/20 0.38
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
ALOX5 P09917 1/20 0.34
TRPA1 O75762 1/20 0.33
CYP3A4 P08684 1/20 0.33
PTPN2 P17706 2/20 0.32
PTPN1 P18031 2/20 0.32
DUSP3 P51452 2/20 0.32
MCHR1 Q99705 1/20 0.32
HPGD P15428 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4620862 0.82 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1CETPACACB
SCHEMBL4620171 0.82 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1CETPACACB
SCHEMBL19251058 0.81 SLC1A3 (0.45) SLC1A3SLC1A2SLC1A1CETPACACB
SCHEMBL1145283 0.76
SCHEMBL3952347 0.75 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1CETPACACB
SCHEMBL649272 0.74 IDO1 (0.44)
SCHEMBL28345414 0.72 CETP (0.41) SLC1A3SLC1A2SLC1A1CETPACACB
SCHEMBL12853955 0.72
SCHEMBL12417069 0.72
SCHEMBL681105 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 WO disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-9440938-B2 Sulfonamide derivative having PGD2 receptor antagonistic activity SHIONOGI & CO., LTD. (JP) 2016-09-13 US disclosed
US-20150158833-A1 SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY SHIONOGI & CO (JP) 2015-06-11 US disclosed
US-8153793-B2 Sulfonamide derivative having PGD2 receptor antagonistic activity SHIONOGI & CO., LTD. (JP) 2012-04-10 US disclosed
US-20070299263-A1 Hydroxy Alkyl Amines Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SLC1A3 745/4885SLC1A2 905/4885SLC1A1 880/4885
US-20150158833-A1 SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY PTGDR, PTGDR2, CNR2 SLC1A3 3703/4885SLC1A2 2002/4885SLC1A1 2720/4885
US-20070299263-A1 Hydroxy Alkyl Amines MAOA, PSEN2, PSEN1 SLC1A3 595/4885SLC1A2 125/4885SLC1A1 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.